The changing landscape in the treatment of metastatic castration-resistant prostate cancer

被引：33

作者：

El-Amm, Joelle ^{[1
]}

Aragon-Ching, Jeanny B. ^{[1
]}

机构：

[1] George Washington Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Washington, DC 20037 USA

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2013年 / 5卷 / 01期

关键词：

Androgen deprivation therapy; chemotherapy; metastatic castration-resistant prostate cancer; vaccine therapy; MITOXANTRONE PLUS PREDNISONE; RANDOMIZED PHASE-II; SIPULEUCEL-T; DOUBLE-BLIND; ANTITUMOR-ACTIVITY; BONE METASTASES; SURVIVAL; DOCETAXEL; MEN; TRIAL;

D O I：

10.1177/1758834012458137

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The past few years have brought increasing advances in the therapeutic management of metastatic castration-resistant prostate cancer with the approval of several agents, including vaccine therapy with sipuleucel-T, second-line chemotherapy with cabazitaxel, the bone-targeted pharmaceutical denosumab, and the novel antiandrogen therapy abiraterone acetate. There are ongoing developments with other agents in the pipeline such as MDV3100 and alpharadin that have shown promising results. This review describes the clinical trials that brought about the drug approvals of various agents and offers some insights regarding a rational approach to optimal treatment sequencing for these drugs since national guidelines are currently lacking.

引用

页码：25 / 40

页数：16

共 67 条

[41] Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants [J].

Mostaghel, Elahe A. ;

Marck, Brett T. ;

Plymate, Stephen R. ;

Vessella, Robert L. ;

Balk, Stephen ;

Matsumoto, Alvin M. ;

Nelson, Peter S. ;

Montgomery, R. Bruce .

CLINICAL CANCER RESEARCH, 2011, 17 (18) :5913-5925

[42] Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer [J].

Ning, Yang-Min ;

Gulley, James L. ;

Arlen, Philip M. ;

Woo, Sukyung ;

Steinberg, Seth M. ;

Wright, John J. ;

Parnes, Howard L. ;

Trepel, Jane B. ;

Lee, Min-Jung ;

Kim, Yeong Sang ;

Sun, Haihao ;

Madan, Ravi A. ;

Latham, Lea ;

Jones, Elizabeth ;

Chen, Clara C. ;

Figg, William D. ;

Dahut, William L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) :2070-2076

[43] Receptor activator of NF-κB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells [J].

Odero-Marah, Valerie A. ;

Wang, Ruoxiang ;

Chu, Gina ;

Zayzafoon, Majd ;

Xu, Jianchun ;

Shi, Chunmeng ;

Marshall, Fray F. ;

Zhau, Haiyen E. ;

Chung, Leland W. K. .

CELL RESEARCH, 2008, 18 (08) :858-870

[44] Critical appraisal of cabazitaxel in the management of advanced prostate cancer [J].

Pal, Sumanta Kumar ;

Twardowski, Przemyslaw ;

Sartor, Oliver .

CLINICAL INTERVENTIONS IN AGING, 2010, 5 :395-402

[45]

Peppercorn J., 2012, UROL ONCOL

[46] Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [J].

Petrylak, DP ;

Tangen, CM ;

Hussain, MHA ;

Lara, PN,J ;

Jones, JA ;

Taplin, ME ;

Burch, PA ;

Berry, D ;

Moinpour, C ;

Kohli, M ;

Benson, MC ;

Small, EJ ;

Raghavan, D ;

Crawford, ED .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1513-1520

[47] Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer [J].

Pili, Roberto ;

Haggman, Michael ;

Stadler, Walter M. ;

Gingrich, Jeffrey R. ;

Assikis, Vasileios J. ;

Bjork, Anders ;

Nordle, Orjan ;

Forsberg, Goran ;

Carducci, Michael A. ;

Armstrong, Andrew J. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (30) :4022-4028

[48] Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer [J].

Rocchi, P ;

So, A ;

Kojima, S ;

Signaevsky, M ;

Beraldi, E ;

Fazli, L ;

Hurtado-coll, A ;

Yamanaka, K ;

Gleave, M .

CANCER RESEARCH, 2004, 64 (18) :6595-6602

[49] Mechanisms of disease: Mechanisms of bone metastasis [J].

Roodman, GD .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) :1655-1664

[50]

Ryan C., 2012, CANCER RES, V72

← 1 2 3 4 5 6 7 →